Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | NT5E | P21589 | 3/20 | 0.53 |
| ▸ | TYMP | P19971 | 9/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.44 |
| ▸ | AHCY | P23526 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | NADK | O95544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065699 | 1.00 | ADORA1 (0.56) | ADORA1NT5ETYMPP2RX3P2RX4 | |
| SCHEMBL3318862 | 0.83 | NT5E (0.73) | ADORA1NT5ETYMPPDE2A | |
| SCHEMBL6271787 | 0.83 | NT5E (0.73) | ADORA1NT5ETYMPPDE2A | |
| SCHEMBL6271785 | 0.83 | NT5E (0.73) | ADORA1NT5ETYMPPDE2A | |
| SCHEMBL6267926 | 0.83 | ADORA1 (0.53) | ADORA1NT5ETYMPP2RX3P2RX4 | |
| SCHEMBL7069141 | 0.82 | TYMP (0.51) | ADORA1NT5ETYMP | |
| SCHEMBL7069143 | 0.82 | TYMP (0.51) | ADORA1NT5ETYMP | |
| SCHEMBL8610210 | 0.80 | ADORA1 (0.61) | ADORA1NT5ETYMPP2RX3P2RX4 | |
| SCHEMBL8610263 | 0.80 | TYMP (0.54) | ADORA1NT5ETYMP | |
| SCHEMBL8610259 | 0.80 | TYMP (0.54) | ADORA1NT5ETYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030204079-A1 | Process for producing 2', 3'-diethy substituted nucleoside derivatives | AJINOMOTO CO., INC (JP) | 2003-10-30 | — | — | US | disclosed |
| US-6579976-B2 | Producing compounds having sugar-moiety hydroxyl groups or halogen atoms reduced in nucleic acids by allowing O-thiocarbonyl derivatives or halogenated derivatives in the sugar-moiety react with hypophosphorous acids or salts | AJINOMOTO CO., INC. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-20020045744-A1 | PROCESS FOR PRODUCING NUCLEIC ACID DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-0999218-A1 | Process for producing nucleoside derivatives | Ajinomoto Co., Inc. (JP) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204079-A1 | Process for producing 2', 3'-diethy substituted nucleoside derivatives | RNGTT, DOHH, NT5C3B | ADORA1 2863/4885NT5E 184/4885TYMP 38/4885 |
| US-20020045744-A1 | PROCESS FOR PRODUCING NUCLEIC ACID DERIVATIVES | RNGTT, OSGEP, PNP | ADORA1 2231/4885NT5E 231/4885TYMP 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.